Reduced incidence of hepatitis C in 9 villages in rural Egypt: Progress towards national elimination goals

被引:17
作者
Shiha, Gamal [1 ,2 ]
Soliman, Reham [1 ,3 ]
Mikhail, Nabiel N. H. [1 ,4 ]
Easterbrook, Philippa [5 ]
机构
[1] Egyptian Liver Res Inst & Hosp ELRIAH, Sherbin, El Mansoura, Egypt
[2] Mansoura Univ, Fac Med, Internal Med Dept, Hepatol & Gastroenterol Unit, Mansoura, Egypt
[3] Port Said Univ, Fac Med, Trop Med Dept, Port Said, Egypt
[4] Assiut Univ, South Egypt Canc Inst, Biostat & Canc Epidemiol Dept, Assiut, Egypt
[5] WHO, Dept Global HIV Hepatitis & STI Programmes, Geneva, Switzerland
关键词
Hepatitis C virus infection; Incidence; Treatment as prevention; Elimination; Egypt; VIRUS-INFECTION; RISK-FACTORS; INJECT DRUGS; TRANSMISSION; PREVENTION; EPIDEMIC; PEOPLE;
D O I
10.1016/j.jhep.2020.09.008
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background & Aims: Egypt has a major HCV burden and a well established treatment programme, with an ambitious goal of HCV elimination. Our aim was to assess the impact of a comprehensive HCV prevention, test and treat programme on the incidence of new HCV infections in 9 villages in rural Egypt. Methods: An HCV "educate, test and treat" project was implemented in 73 villages across 7 governorates in Egypt between 06/2015 and 06/2018. In 2018, in 9 of the villages we re-tested individuals who originally tested HCV antibody (HCV-Ab) and HBsAg negative using rapid diagnostic tests (RDTs); confirmatory HCV RNA testing was performed for positive cases. The incidence rate per 1,000 person-years (py) was calculated, and risk factors for incident HCV infections assessed through an interviewer-administered questionnaire in 1:3 age- and gender-matched cases and controls. Results: Out of 20,490 individuals who originally tested HCV-Ab negative in the 9 villages during the 2015-2016 implementation of the "educate, test and treat" programme, 19,816 (96.7%) were re-tested in 2018. Over a median of 2.4 years (IQR 2.1-2.7), there were 19 new HCV infections all of which were HCV RNA positive (incidence rate 0.37/1,000 py) (95% CI 0.24-0.59). Compared to a previous estimate of incidence in the Nile Delta region (2.4/1,000 py) from 2006, there was a substantial reduction in overall incidence of new HCV infections. Exposures through surgery (odds ratio 51; 95% CI 3.5-740.1) and dental procedures (odds ratio 23.8; 95% CI 2.9-194.9) were significant independent predictors of incident infections. Conclusions: This is the first study to show a substantial reduction in incidence of new HCV infections in a sample of the general population in Egypt following attainment of high testing and treatment coverage. New infections were significantly associated with healthcare-associated exposures. Lay summary: Egypt has a major national HCV testing and treatment programme with the goal of eliminating HCV infection. We assessed the impact of a comprehensive HCV prevention, test and treat programme in 73 villages that achieved high coverage of testing and treatment on the subsequent incidence of new HCV infections in nine of the villages. We re-tested people who were previously HCV antibody negative and found that the rate of new HCV infections was greatly reduced compared to previous estimates. We also found that exposure through surgery and dental procedures were associated with these new infections. This highlights the importance of continued strengthening of infection control and prevention measures, alongside treatment scale-up. (C) 2020 World Health Organization; licensee Elsevier.
引用
收藏
页码:303 / 311
页数:10
相关论文
共 35 条
  • [1] [Anonymous], 2019, AUSTR PROGR HEP C EL
  • [2] [Anonymous], 1993, International Ethical Guidelines for Biomedical Research Involving Human subjects
  • [3] Impact of treatment on hepatitis C virus transmission and incidence in Egypt: A case for treatment as prevention
    Ayoub, H. H.
    Abu-Raddad, L. J.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2017, 24 (06) : 486 - 495
  • [4] Towards realistic estimates of HCV incidence in Egypt
    Breban, R.
    Doss, W.
    Esmat, G.
    Elsayed, M.
    Hellard, M.
    Ayscue, P.
    Albert, M.
    Fontanet, A.
    Mohamed, M. K.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2013, 20 (04) : 294 - 296
  • [5] National treatment programme of hepatitis C in Egypt: Hepatitis C virus model of care
    El-Akel, W.
    El-Sayed, M. H.
    El Kassas, M.
    El-Serafy, M.
    Khairy, M.
    Elsaeed, K.
    Kabil, K.
    Hassany, M.
    Shawky, A.
    Yosry, A.
    Shaker, M. K.
    ElShazly, Y.
    Waked, I.
    Esmat, G.
    Doss, W.
    [J]. JOURNAL OF VIRAL HEPATITIS, 2017, 24 (04) : 262 - 267
  • [6] El-Zanaty F., 2015, CAIRO EGYPT MINISTRY
  • [7] El-Zanaty FH., 2006, Egypt demographic and health survey 2008
  • [8] Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model
    Granich, Reuben M.
    Gilks, Charles F.
    Dye, Christopher
    De Cock, Kevin M.
    Williams, Brian G.
    [J]. LANCET, 2009, 373 (9657) : 48 - 57
  • [9] Elimination of Hepatitis C Virus Infection Among People Who Inject Drugs Through Treatment as Prevention: Feasibility and Future Requirements
    Grebely, Jason
    Matthews, Gail V.
    Lloyd, Andrew R.
    Dore, Gregory J.
    [J]. CLINICAL INFECTIOUS DISEASES, 2013, 57 (07) : 1014 - 1020
  • [10] Effect of Universal Testing and Treatment on HIV Incidence - HPTN 071 (PopART)
    Hayes, Richard J.
    Donnell, Deborah
    Floyd, Sian
    Mandla, Nomtha
    Bwalya, Justin
    Sabapathy, Kalpana
    Yang, Blia
    Phiri, Mwelwa
    Schaap, Ab
    Eshleman, Susan H.
    Piwowar-Manning, Estelle
    Kosloff, Barry
    James, Anelet
    Skalland, Timothy
    Wilson, Ethan
    Emel, Lynda
    Macleod, David
    Dunbar, Rory
    Simwinga, Musonda
    Makola, Nozizwe
    Bond, Virginia
    Hoddinott, Graeme
    Moore, Ayana
    Griffith, Sam
    Sista, Nirupama Deshmane
    Vermund, Sten H.
    El-Sadr, Wafaa
    Burns, David N.
    Hargreaves, James R.
    Hauck, Katharina
    Fraser, Christophe
    Shanaube, Kwame
    Bock, Peter
    Beyers, Nulda
    Ayles, Helen
    Fidler, Sarah
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 381 (03) : 207 - 218